PVI
RNTX

Pura Vida Investments’s Rein Therapeutics RNTX Stock Holding History

Pura Vida Investments’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-6,777
Closed -$91K – 125
2019
Q3 		$91K Buy
+6,777
New +$93.8K 0.02% 90

Other funds holding RNTX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
BBVA
Banco Bilbao Vizcaya Argentaria Madrid, Spain $14.3B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPFA
Game Plan Financial Advisors Westlake, Ohio $222M AUM 22.82% 1-Year Est. Return
IWAG
Integer Wealth Advisors Group Cartersville, Georgia $184M AUM 62.15% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return

Pura Vida Investments's RNTX Position: Q4 2019 in Review

Pura Vida Investments sold out of Rein Therapeutics (RNTX) in Q4 2019, closing a stake of 6,777 shares — an estimated $91K sold.

Pura Vida Investments first reported a position in RNTX in Q3 2019 and held it in 1 quarter. The position peaked at $91K in Q3 2019. 17 funds tracked by Wall St. Rank hold RNTX as of Q4 2019.

  • Pura Vida Investments reported no remaining Rein Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Pura Vida Investments sold 6,777 Rein Therapeutics shares in Q4 2019, an estimated $91K.
  • Pura Vida Investments first reported a position in Rein Therapeutics in Q3 2019 and held it in 1 quarter.
  • Pura Vida Investments's Rein Therapeutics position peaked at $91K in Q3 2019.
  • 17 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2019.

Based on Pura Vida Investments's 13F filing for Q4 2019, filed 14 Feb 2020.